Dr. Shaji Kumar on Upfront Combination Treatments in Multiple Myeloma

Shaji Kumar, MD
Published: Monday, Aug 15, 2016


Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the impact of combination treatments upfront in multiple myeloma.
 
Using several novel agents in combination upfront— such as bortezomib, lenalidomide, and dexamethasone—has been shown to improve survival. Other triplet combinations, such as carfilzomib-lenalidomide-dexamethasone have also shown promise in multiple myeloma.
 
These triplet combinations make it more likely that a patient will experience a deep response, and in turn experience longer overall survival (OS), said Kumar. Even if they do not experience longer OS, progression-free survival (PFS) may be improved with a triplet combination, which can improve quality of life, he said.
 
Often, patients can not go back on a drug once they have progressed on it, but the data that is available right now suggests that the benefit patients get by combining different classes of drugs in the upfront setting is worth the drug not being available to them later on.
 

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the impact of combination treatments upfront in multiple myeloma.
 
Using several novel agents in combination upfront— such as bortezomib, lenalidomide, and dexamethasone—has been shown to improve survival. Other triplet combinations, such as carfilzomib-lenalidomide-dexamethasone have also shown promise in multiple myeloma.
 
These triplet combinations make it more likely that a patient will experience a deep response, and in turn experience longer overall survival (OS), said Kumar. Even if they do not experience longer OS, progression-free survival (PFS) may be improved with a triplet combination, which can improve quality of life, he said.
 
Often, patients can not go back on a drug once they have progressed on it, but the data that is available right now suggests that the benefit patients get by combining different classes of drugs in the upfront setting is worth the drug not being available to them later on.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x